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Between 1959 and 1963 100 million or more Americans received
inactivated or live attenuated poliovirus vaccines inadvertently
contaminated with simian virus 40 (SV40) (Sweet and Hilleman,
1960; Shah and Nathanson, 1976). SV40 was present in monkey
kidney tissue used for propagation of poliovirus. SV40 is onco-
genic in newborn hamsters following parenteral inoculation. SV40
serologic studies of human recipients and attempts to recover virus
from those given live vaccine yielded suggestive but inconclusive
results (Sweet and Hilleman, 1960; Gerber et al, 1961; Shah and
Nathanson, 1976). 
Subsequent population-based studies in the United States,
Germany and Sweden have not provided evidence of excess
cancer incidence in persons exposed to SV40 in poliovirus
vaccines (Geissler, 1990; Olin and Geisecke, 1998; Strickler and
Goedert, 1998; Strickler et al, 1998). However, reports have
appeared of SV40 DNA fragments found by PCR in certain
uncommon human tumours, such as ependymomas, other brain
neoplasms, osteosarcomas in children, and mesotheliomas in
adults (Butel and Lednicky, 1999). To some extent this spectrum
of tumours parallels that occurring in SV40-infected animals
(Stenton, 1998). Uncertainties in, and alternative explanations for,
these observations prevent firm conclusions (Geissler, 1990;
Carbone et al, 1994; Strickler et al, 1996; Shah et al, 1997; Butel
and Lednicky, 1999). 
This study is a follow-up of 1073 individuals who received
poliovirus vaccines at one to three days of age in 1960 or 1962 
in Cuyahoga County, Ohio, to try to determine their immuno-
genicity in the neonatal period (Lepow et al, 1962). These
subjects are unique because the vaccines were shown to contain
live SV40 and, like the hamsters who developed SV40-related
tumours, they were exposed to SV40 at an age of presumed
immunologic immaturity. Previous follow-ups (Fraumeni et al,
1970; Mortimer et al, 1981) uncovered no deaths due to cancer.
The recent identification of SV40 DNA fragments in some
tumours from other studies has reawakened interest in this
cohort. 
SUBJECTS AND METHODS 
To identify deaths of study subjects subsequent to the 1981 report
(Mortimer et al, 1981) we used the National Death Index (NDI)
which is maintained by the National Center for Health Statistics
(NCHS). The NDI was established in 1979 to provide an accurate
national method for ascertaining deaths of individuals partici-
pating in medical, epidemiologic and other long-term health inves-
tigations of large mobile populations (Patterson and Bilgrad,
1986). Data regarding each death are provided to the NDI by the
states electronically from the death certificates, and include 14
identifying items, although all 14 are not always available. The
NDI search protocol initially comprises a comparison of the
researcher’s data with the NDI database on 7 specific items to
develop a list of potential matches. These potential matches are
then subjected to further analyses using the remaining 7 criteria to
ascertain their accuracy. The researcher is provided a listing of any
matches in descending order of probability including the state in
which the death certificate is located. For what appear to be certain
matches the NDI also provides the underlying cause of death.
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decided by the researcher. Contact with providers or family
members is usually not permitted without consent of the state of
death. 
15 of the original study group of 1073 infants were known to be
deceased by 1979. Information on subjects collected from birth
through 1979, including addresses, telephone numbers, and names
of parents, siblings and in some instances other family members
and contacts, was available. The names and identifying data for
the 1058 study subjects believed to be alive in 1979 were
submitted to the NDI. The study was approved by the human
subjects review boards of the two hospitals where the subjects
were born, and by the jurisdictions from which copies of the death
certificates were requested when required. 
We compared observed and expected numbers of deaths, for
various causes, for the period from 1969 (the first year systematic
data on non-cancer deaths were available from NCHS) to 1996
(the most recent year for which NDI data were available).
Observed deaths were derived from prior follow-up studies
(Fraumeni et al, 1970; Mortimer et al, 1981) for 1969–78 and from
the NDI search for 1979–96. The expected numbers of deaths 
from various causes, 1969–96, were determined using NCHS 
sex-, age-, race- and year-specific mortality rates for Cuyahoga
County, Ohio, the area from which the subjects were drawn. Sex or
race data were not available for 18 and 797 subjects, respectively.
To calculate expected rates, therefore, we imputed fractional
values of sex (50% male) and race (83% black, 17% white based
on the composition of the remaining cohort. In sensitivity analyses
in which we varied these fractions over a range of reasonable
values (40–60% for male sex, 70–90% for black race), we found
the expected rates for cancer outcomes changed little (data not
shown). 
We estimated expected numbers of deaths for all cancers
combined and for those specific cancers that actually occurred 
in deceased cohort members. Additionally, we estimated the
expected numbers of non-cancer deaths, total and cause-specific
for observed non-cancer deaths. Relative risks were calculated for
each cause of death (observed deaths divided by expected deaths)
(Hennekens and Buring, 1987). Exact confidence intervals and
two-sided P values for these relative risks were determined using
the Poisson distribution. 
RESULTS 
The search of the NDI data produced 577 potential matches with
study subjects. As ranked by NCHS, the vast majority of these
were unlikely to be true matches. Two study personnel indepen-
dently reviewed each potential match and eliminated 432 for
whom the date of birth differed by more than one year and the state
of birth was not Ohio. To ensure that no possible matches were
missed, death certificates were requested for the remaining 145
subjects even though some of the data items did not match. These
included records that had a phonetic match on one or more names,
or had one mismatch in the date of birth (either month, or day, 
or +/– 1 year). Each death certificate was then compared to the
original subject records. Agreement on the parents’ names and the
date and location of birth as well as subject name was necessary 
to validate each match. 
A total of 44 deaths in study subjects were identified (Table 1).
Of these, 41 death certificates were obtained through the informa-
tion provided by the NDI, one was found as a result of a pilot study
to assess the feasibility of locating living subjects 20 years after
the last contact, and one case occurred in 1977 and was reported
previously (Mortimer et al, 1981). The death certificate of a 44th
person with an identical, though common, given name, surname,
middle initial, birth date, and residence in Ohio at birth and at
death according to the NDI could not be located by the state’s
Division of Vital Statistics, and search of the medical records of
the two study hospitals was non-productive. We and the NDI
considered this death to be a probable match and it is included in
Table 1. 
Table 1 shows the causes of death of these 44 persons. There
were 3 deaths from cancer confirmed by death certificates. Two
were due to testicular tumours and one to myelogenous leukaemia.
A fourth cancer death (the probable match noted above) was a case
of lymphatic leukaemia. Although there were only two cases of
testicular cancer, the relative risk was 37.9 (P = 0.002). Also, the
relative risk of leukaemia was 4.2 with two cases but this was not
significant (P = 0.16). Overall, the relative risk of cancer death (all
types combined) was 1.27. All 4 subjects who died of cancer had
received live, attenuated vaccine as newborns. 
We identified no death from brain tumours, osteosarcomas or
mesotheliomas. For all cancers other than testicular cancer and
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Table 1 Observed and expected causes of death in 44 persons, 1969 to 1996, who received SV40-
contaminated poliovirus vaccine as newborns in 1960 or 1962 
Cause of death ICD9 Nos. Observed Expected RR 95% CL 
All 44 47.15 0.93 0.67–1.25 
All cancer 140–208, 235–239 4 3.16 1.26 0.34–3.23 
Testis 186 2 0.05 36.98 4.47–133.50 
Leukaemia 204–208 2 0.48 4.19 0.51–15.73 
Other cancer Residual 0 2.62 ––  
Non-cancer 40 44.00 0.90 0.64–1.23 
External E800–E999 28 26.91 1.04 0.69–1.50 
Homicide E960–E978 16 13.53 1.18 0.67–1.91 
Suicide E950–E959 5 3.75 1.33 0.43–3.10 
Trauma E800–E949 7 7.42 0.94 0.38–1.94 
Automobile E810–E825 6 4.32 1.39 0.51–3.03 
Other trauma E800–E809, E826–E949 1 3.10 0.32 0.01–1.78 
AIDS 024–044 4 3.84 1.04 0.28–2.66 
Other non-cancer Residual 8 13.24 0.60 0.26–1.18 
ICD9 numbers used for calculation of expected deaths, RR = relative risk, 95% CL = 95% confidence limits. leukaemia, the risk actually appeared decreased (no observed
deaths vs. 2.62 expected deaths). 
Most of the non-cancer deaths were due to violence and other
extrinsic causes and rates were similar to those expected in these
age, sex and ethnic groups, suggesting that the lack of an overall
increase in cancer mortality in the SV40-exposed cohort was not
due to under-ascertainment of deaths. 
DISCUSSION 
After more than 35 years of follow-up, we found no overall excess
of deaths from cancer in these individuals who as infants received
poliovirus vaccines contaminated with SV40. The results are reas-
suring, consonant with other epidemiological studies (Geissler,
1990; Olin and Geisecke, 1998; Strickler and Goedert, 1998;
Strickler et al, 1998), and of special interest because the vaccines
were given in the very early newborn period, the age of highest
risk for oncogenesis induced by SV40 in the hamster model.
Notably absent were deaths from tumours induced by SV40 in
laboratory animals, including brain tumours, osteosarcomas and
mesotheliomas. 
Of some interest are the 2 deaths from testicular cancer. One
died at 21 years, and the other at 31 years. Testicular tumours have
not been observed in animals infected with SV40 and there is no
report of SV40 fragments in human testicular tumours. However,
SV40 antigens have been described in normal human sperm fluids
(Martini et al, 1996). Although it is conceivable that SV40 infec-
tion caused testicular cancer in these subjects, at least 2 other
explanations are more likely. One obvious explanation is that the
apparent excess is due to chance related to multiple comparisons.
There were in effect many implied comparisons in this study in
that a search of the NDI was made for deaths due to any and all
causes of death, the vast majority of which did not appear. It is also
relevant that whereas expected values can, as here, be small frac-
tions, observed numbers have to be whole numbers. Another
possibility is that, due to their predominately low socioeconomic
status, our subjects were at higher risk for mortality from this
usually curable tumour because of delayed recognition and treat-
ment; but on the other hand testicular cancer exhibits higher rates
in higher socioeconomic groups. Nonetheless, further study of this
association in humans is needed. 
We found a relative risk for death due to leukaemia of 4.2. SV40
has been shown to induce leukaemia and lymphomas in hamsters
(Diamandopoulos, 1972). Interestingly, 2 previous studies reported
detection of SV40 in human haematological malignancies (Martini
et al, 1998; Rizzo et al, 1999). The significance of these results is
unclear (Rizzo et al, 1999), since positive results have also been
observed in blood specimens from healthy controls (Martini et al,
1996; Martini et al, 1998) and additional studies confirming such an
association have not, to our knowledge, been reported. The 2
leukaemia cases differed in cell types (one myelogenous and one
lymphatic). The association between SV40 and leukaemia did not
achieve statistical significance and, like the association with testic-
ular cancer, there may be explanations other than causality. 
There are several limitations to these results. First, the 35 to 37
year duration of follow-up may be inadequate for some neoplasms
implicated in the pathologic studies, such as mesotheliomas,
although the central nervous system tumours with identified SV40
fragments are primarily those of childhood and would be expected
to have a much shorter latent period. Secondly, the relatively small
number of subjects compromises a study of site-specific lesions.
Finally, it is possible that some deceased subjects were not identi-
fied by the NDI. This would particularly involve females whose
names changed due to marriage. However, mortality from non-
cancer causes was not low among females, which would have been
the case if they were under-ascertained (data not shown). 
Future studies of this cohort may prove informative. For
example, it may be possible to utilize cancer registry data for the
Cleveland area to ascertain cancer incidence, which could provide
complementary data to the present study. Also, because the age 
of the subjects at the time of this follow-up was 35 to 37 years,
considerably younger than the ages at which some neoplasms
usually occur, the records of this cohort are being retained for
possible future use if warranted by other laboratory and epidemio-
logic information. 
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